<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077467</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01809</org_study_id>
    <secondary_id>ADVL0317</secondary_id>
    <secondary_id>CDR0000350340</secondary_id>
    <secondary_id>COG-ADVL0317</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00077467</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia</brief_title>
  <official_title>A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of bortezomib in treating young&#xD;
      patients with refractory or recurrent leukemia. Bortezomib may stop the growth of cancer&#xD;
      cells by blocking the enzymes necessary for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Primary I. Determine the maximum tolerated dose and recommended phase II dose of&#xD;
      bortezomib in children with refractory or recurrent leukemia.&#xD;
&#xD;
      II. Determine the toxic effects of this drug in these patients. III. Determine the&#xD;
      pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary I. Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      II. Determine, preliminarily, the biologic activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label, multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every&#xD;
      21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 1.5-36&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended phase II dose</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics as assessed by confidence intervals (CI), area under the curve (AUC), and half-life (T ½)</measure>
    <time_frame>Pretreatment, days 1, 8, 18-22 of course 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate apoptosis and NF-kB activation</measure>
    <time_frame>Prestudy, days 8 and 18</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Acute Promyelocytic Leukemia (M3)</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed leukemia of 1 of the following types:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in blast crisis&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  Immunophenotypically confirmed disease, either at initial diagnosis or relapse&#xD;
&#xD;
          -  More than 25% blasts in the bone marrow (M3 bone marrow)&#xD;
&#xD;
          -  Active extramedullary disease (except leptomeningeal disease) allowed&#xD;
&#xD;
          -  No known curative therapy or therapy proven to prolong survival with an acceptable&#xD;
             quality of life available&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (for patients age 11 to 21)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (for patients age 10 and under)&#xD;
&#xD;
          -  Platelet count ≥ 20,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL*&#xD;
&#xD;
          -  WBC &lt; 20,000/mm^3** (hydroxyurea for cytoreduction allowed)&#xD;
&#xD;
          -  No hyperleukocytosis (i.e., WBC &gt; 100,000/mm^3)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL for patients age 5 and under&#xD;
&#xD;
               -  ≤ 1.0 mg/dL for patients age 6 to 10&#xD;
&#xD;
               -  ≤ 1.2 mg/dL for patients age 11 to 15&#xD;
&#xD;
               -  ≤ 1.5 mg/dL for patients age 16 to 21&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  At least 7 days since prior biologic agents&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue and no evidence of&#xD;
             active graft-versus-host disease&#xD;
&#xD;
          -  No concurrent prophylactic G-CSF during course 1 of study&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea for cytoreduction&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  At least 7 days since prior steroids (except as premedication prior to blood product&#xD;
             transfusion)&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior small port local palliative radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior total body irradiation, craniospinal irradiation, or&#xD;
             irradiation to more than 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 7 days since prior retinoids&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No concurrent anticonvulsant medications known to activate the cytochrome p450 system&#xD;
             (e.g., phenytoin, carbamazepine, or phenobarbital)&#xD;
&#xD;
               -  Concurrent benzodiazepines and gabapentin are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terzah Horton</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COG Phase I Consortium</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

